Business
Medicenna Therapeutics Opens the Market
Medicenna Therapeutics Opens the Market Canada NewsWire TORONTO and HOUSTON, May...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Therapeutics Opens the Market\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, May 25, 2017\n\n\n\nTORONTO and HOUSTON, May 25, 2017 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSXV: MDNA) announced that members of senior management, directors, advisors and key stakeholders of Medicenna will open the market at the Toronto Stock Exchange today. The Company began trading on the TSX Venture Exchange (TSXV) on March 8, 2017.\n\n\"We are honoured to be invited to open the market and celebrate our recent listing on the TSX Venture Exchange,\" said Dr. Fahar Merchant, Chairman, President and CEO of Medicenna. \"Listing on the TSXV was the first in a series of value generating milestones we hope to achieve in the next twelve months. With our recent fund raising efforts, a non-dilutive grant from the Cancer Prevention and Research Institute of Texas (\"CPRIT\") and executive and board appointments, the building blocks for advancing our company's immuno-oncology pipeline are firmly in place. We continue to enroll patients in our Phase 2b clinical trial for recurrent glioblastoma (\"rGB\"), a deadly and uniformly fatal type of brain cancer, and expect top-line results early next year. In addition, we plan to commence enrolment in a Phase 2 clinical trial in metastatic brain cancer later this year while continuing to advance our pre-clinical pipeline.\"\n\nFollowing the completion of a qualifying transaction and associated $4 million private placement, the Company's shares began trading on the TSXV on March 8, 2017 under the symbol \"MDNA\". In addition to a $14M USD grant from CPRIT, Medicenna closed a series of private placements raising approximately $14M CAD during the past year.\n\nMedicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs).  Its wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4...